The Five-Dollar Dose
A peer-reviewed cost analysis shows Merck's once-monthly HIV prevention pill could be manufactured for $4.46 per person per year. The trials aren't even done yet — and 177 advocacy groups are already demanding Merck license generics now.
Photo: Jeffrey Beall / Wikimedia Commons
Every day, 3,500 people contract HIV — 1.3 million new infections per year. Daily PrEP pills work, but adherence is brutal: globally, only 3.5 million people use PrEP against a UNAIDS target of 21.2 million. The gap isn't science. It's logistics.
Merck's MK-8527 is a once-monthly oral pill now in two Phase 3 trials enrolling over 9,000 participants across 16 countries. Phase 2 data showed protection within 24 hours and drug levels sustained beyond 28 days. A cost analysis published in the journal *AIDS* found it could be manufactured for $4.46–$24.91 per person per year — less than a dollar a pill.
In February, 177 advocacy organizations from 30 countries sent Merck an open letter demanding generic licensing through the Medicines Patent Pool before regulatory approval. UNAIDS director Winnie Byanyima has publicly pushed Merck to act. The tactic is new: establish the generic price floor while trials are still running, turning clinical access into licensing leverage.
Our take
The playbook is changing: activists are publishing manufacturing cost analyses during Phase 3 trials, not after approval. By proving a $5 production cost while Merck still needs enrollment sites in Africa, they've turned clinical trial access into licensing leverage. This preemptive approach — establishing the generic price floor before the brand price exists — could reshape access negotiations for every pipeline drug in global health.
What to do with this
Commission preemptive cost-of-goods analyses for pipeline drugs now, not post-approval. The $5 figure exists because researchers did the work early — replicate for TB, malaria, and NCD drugs still in trials.
Begin regulatory pre-qualification for MK-8527 generics before Phase 3 results land in late 2027. Countries with advance pathways will get access a year faster.
Use this case to build a standard playbook — cost analysis + open letter + licensing demand — for every promising pipeline drug while Phase 3 is still running.
Go deeper
Related innovations
One proven innovation daily. Free.